Imaging Technology

JANUARY 5, 2024

This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 ( 64 Cu) for imaging and alpha-particle targeted RPT using lead-212 ( 212 Pb). milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.

Radiopharmaceuticals 104

Radiopharmaceuticals Clinic Nuclear Medicine Radiation 104

Imaging Technology

SEPTEMBER 20, 2023

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

Pharmaceutical 105

Pharmaceutical Radiopharmaceuticals Radiation Diagnostic 105

Imaging Technology

APRIL 10, 2024

an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,

Radiopharmaceuticals 105

Radiopharmaceuticals Radiosensitivity Medical Diagnostic 105

Health Imaging

JULY 29, 2024

According to the DOJ, the pharmacist and those working under him “would ‘fractionate’ or ‘split’ the active ingredient of Technescan MAG3, without ensuring the pieces were equal in size, purity or strength.”

Radiopharmaceuticals 111

Radiopharmaceuticals 111

Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 98

Radiopharmaceuticals Imaging Pharmaceutical Disease 98

Open Medscience

JANUARY 1, 2024

Zirconium radiopharmaceuticals enhance nuclear medicine with precise diagnostics and potential therapeutic applications. The post Zirconium Radiopharmaceuticals in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Health Imaging

JANUARY 8, 2024

The new facility is run by Novartis and is being called the “most advanced of its kind."

Radiopharmaceuticals 110

Radiopharmaceuticals IT 110

Open Medscience

DECEMBER 31, 2023

Lutetium radiopharmaceuticals significantly advance targeted cancer treatment and diagnostic capabilities. The post Lutetium Radiopharmaceuticals in Medicine: A Comprehensive Review appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Diagnostic Medical Imaging 59

Open Medscience

JANUARY 24, 2024

The post The Breakthrough Role of Thorium-227 in Theranostic Radiopharmaceuticals appeared first on Open Medscience. Thorium-227 emerges in nuclear medicine, revolutionizing cancer treatment through precise, effective radiotheranostic and therapeutic applications.

Radiopharmaceuticals 64

Radiopharmaceuticals Nuclear Medicine 64

Imaging Technology

JUNE 15, 2023

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

Radiopharmaceuticals 98

Radiopharmaceuticals Pharmaceutical Nuclear Medicine PET Scan 98

Open Medscience

DECEMBER 28, 2023

Lead radiopharmaceuticals herald a transformative era in cancer treatment with promising, targeted therapeutic approaches. The post Transforming Cancer Treatment: The Promising Future of Lead Radiopharmaceuticals appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical 59

Open Medscience

NOVEMBER 17, 2023

Gallium, predicted by Mendeleev, now revolutionises medical diagnostics with its unique radiopharmaceutical applications in oncology. The post Gallium Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical Imaging Medical Imaging 59

Open Medscience

FEBRUARY 28, 2024

Exploring the evolving role of radiopharmaceutical diagnostics in enhancing disease detection and personalising treatment in modern medicine. The post Radiopharmaceutical Diagnostics and Imaging Technologies appeared first on Open Medscience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Imaging Disease 52

Imaging Technology

JULY 11, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 75

Radiopharmaceuticals Imaging Pharmaceutical Disease 75

Radiology Business

OCTOBER 31, 2024

Leaders said the funding will help Blue Earth to further advance its development of PSMA-targeted therapies for prostate cancer.

Radiopharmaceuticals 110

Radiopharmaceuticals Imaging IT 110

Open Medscience

NOVEMBER 23, 2024

Radiopharmaceutical therapy in cancer offers targeted treatment, minimising side effects while enhancing patient outcomes The post Radiopharmaceutical Therapy in Cancer: A Beacon of Hope in Oncology appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals 52

Radiology Business

SEPTEMBER 10, 2024

NRC estimates that 29 of these “medical events” occurred between 2021 and 2023, with “many” involving new therapeutic radiopharma procedures.

Radiopharmaceuticals 114

Radiopharmaceuticals Medical 114

Radiology Business

MAY 3, 2024

The Swiss drugmaker said the deal will bolster its research infrastructure and clinical supply capabilities, with an eye toward improving oncologic care.

Radiopharmaceuticals 114

Radiopharmaceuticals Clinic IT 114

Open Medscience

NOVEMBER 11, 2023

Copper radiopharmaceuticals offer groundbreaking diagnostic and therapeutic applications, revolutionising nuclear medicine, particularly in oncology and cardiology. The post Exploring Copper Radiopharmaceuticals: Innovations and Applications in Nuclear Medicine appeared first on Open Medscience.

Nuclear Medicine 59

Nuclear Medicine Radiopharmaceuticals Diagnostic Medical 59

Open Medscience

NOVEMBER 16, 2023

In Brazil, the growing radiopharmaceutical market, driven by chronic disease and advanced imaging technologies, is becoming increasingly significant in healthcare. The post Advancing Healthcare: The Dynamic Growth of Brazil’s Radiopharmaceutical Market appeared first on Open Medscience.

Radiopharmaceuticals 59

Radiopharmaceuticals Healthcare Healthcare Disease 59

AuntMinnie

MAY 8, 2024

Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer.

Radiopharmaceuticals 75

Radiopharmaceuticals Nuclear Medicine Radiation Hospital 75

Radiology Business

MAY 21, 2024

The Indianapolis-based drugmaker can hit the hefty total by reaching certain clinical, regulatory and commercial milestones.

Radiopharmaceuticals 110

Radiopharmaceuticals Clinic 110

Open Medscience

JANUARY 12, 2024

Radiopharmaceuticals, combining radioactive and pharmaceutical elements, enable precise diagnosis and treatment in nuclear medicine. The post The Transformative Impact of Radiopharmaceuticals in Medical Imaging appeared first on Open Medscience.

Radiopharmaceuticals 52

Radiopharmaceuticals Medical Imaging Nuclear Medicine Medical 52

Open Medscience

AUGUST 11, 2024

Adhering to environmental regulations in radiopharmaceutical production ensures safety, reduces waste, and protects the surrounding ecosystem. The post Ensuring Environmental Compliance and Control in Radiopharmaceutical Production appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Patient Safety Nuclear Medicine 52

Open Medscience

JUNE 17, 2024

Radiopharmaceuticals play a crucial role in heart imaging, enabling accurate diagnosis and effective treatment of various cardiac conditions. The post Radiopharmaceuticals in Heart Imaging for Diagnosis and Treatment appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Imaging 52

Open Medscience

NOVEMBER 12, 2023

The post Technetium-99m Radiopharmaceuticals in Advanced Medical Imaging appeared first on Open Medscience. Technetium-99m, discovered in 1937, transformed medical imaging with its versatile and safe diagnostic applications.

Radiopharmaceuticals 59

Radiopharmaceuticals Medical Imaging Medical Imaging 59

Radiology Business

OCTOBER 7, 2024

Founded in 2019, the firm is focused on developing products for the diagnosis and therapy of blood cancers and other indications not addressed by nuclear medicine.

Nuclear Medicine 105

Nuclear Medicine Radiopharmaceuticals 105

Radiology Business

OCTOBER 1, 2024

The Boston clinical stage biotechnology company is working to develop new products to treat a range of solid tumors.

Radiopharmaceuticals 105

Radiopharmaceuticals Clinic 105

Radiology Business

JULY 12, 2024

For years, the agency has packaged payment for nuclear imaging agents with the procedure, but this has created a barrier for those who require pricier new drugs.

Radiopharmaceuticals 104

Radiopharmaceuticals Diagnostic Imaging 104

Open Medscience

AUGUST 11, 2024

Radiopharmaceuticals in diagnostics provide critical insights into disease processes, improving accuracy, patient care, and treatment outcomes significantly. The post The Transformative Power of Radiopharmaceuticals in Diagnostics appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnostic Patient Care Disease 52

Open Medscience

JUNE 23, 2024

What are radiopharmaceuticals? The post What are Radiopharmaceuticals? They are radioactive drugs used for diagnosing and treating various medical conditions. An Insight into Their Role and Applications appeared first on Open MedScience.

Radiopharmaceuticals 52

Radiopharmaceuticals Diagnose Medical 52

Radiology Business

JUNE 28, 2024

One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.

Radiopharmaceuticals 105

Radiopharmaceuticals Diagnostic 105

Open Medscience

OCTOBER 1, 2024

The post Overview of Good Manufacturing Practices (GMP) in Radiopharmaceuticals appeared first on Open MedScience. Good Manufacturing Practices ensure the consistent quality, safety, and efficacy of pharmaceutical products through rigorous production standards.

Radiopharmaceuticals 52

Radiopharmaceuticals Pharmaceutical 52

Diagnostic Imaging

JUNE 28, 2023

discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.

Radiopharmaceuticals 68

Radiopharmaceuticals Nuclear Medicine Imaging 68

Diagnostic Imaging

JANUARY 12, 2024

The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.

Radiopharmaceuticals 132

Radiopharmaceuticals 132

Open Medscience

MARCH 22, 2024

The post Nuclear Medicine at the Centre of Radiology and Radiopharmaceuticals appeared first on Open Medscience. Nuclear medicine and the future of precise, personalised care in diagnosing and treating diseases.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiology Disease 52

Radiology Business

NOVEMBER 20, 2024

The Australian company will secure exclusive worldwide rights to a suite of diagnostic and therapeutic candidates geared toward urological cancers.

Radiopharmaceuticals 105

Radiopharmaceuticals Imaging Diagnostic 105